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Abstract
Tumour invasion and metastasis is the most common cause of death from cancer. For epithelial cells to invade surrounding
tissues and metastasise, an epithelial-mesenchymal transition (EMT) is required. We have demonstrated that FGFR1
expression is increased in bladder cancer and that activation of FGFR1 induces an EMT in urothelial carcinoma (UC) cell lines.
Here, we created an in vitro FGFR1-inducible model of EMT, and used this model to identify regulators of urothelial EMT.
FGFR1 activation promoted EMT over a period of 72 hours. Initially a rapid increase in actin stress fibres occurred, followed
by an increase in cell size, altered morphology and increased migration and invasion. By using site-directed mutagenesis
and small molecule inhibitors we demonstrated that combined activation of the mitogen activated protein kinase (MAPK)
and phospholipase C gamma (PLCc) pathways regulated this EMT. Actin stress fibre formation was regulated by PLCc
activation, and was also important for the increase in cell size, migration and altered morphology. MAPK activation
regulated migration and E-cadherin expression, indicating that combined activation of PLCcand MAPK is required for a full
EMT. We used expression microarrays to assess changes in gene expression downstream of these signalling cascades. COX-2
was transcriptionally upregulated by FGFR1 and caused increased intracellular prostaglandin E2 levels, which promoted
migration. In conclusion, we have demonstrated that FGFR1 activation in UC cells lines promotes EMT via coordinated
activation of multiple signalling pathways and by promoting activation of prostaglandin synthesis.
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Introduction
Epithelial to mesenchymal transition (EMT) is a process that
was observed initially in embryonic development but more
recently has been implicated as a mechanism for cancer metastasis
[1,2]. Although tumour invasion and metastasis is the major cause
of death in cancer patients, the biological mechanisms of
metastasis remain incompletely understood. The majority of adult
solid tumours are derived from an epithelial lineage. Epithelial
cells form layers of cells that are closely adjoined by specialised
membrane structures and such cells are generally non-motile
under normal conditions. For epithelial cancer cells to invade into
surrounding tissues and establish secondary tumours at distant sites
they must lose cell-cell adhesions and polarity and increase their
motility. Understanding the complex mechanisms that drive these
changes in EMT is key to developing therapeutic strategies to both
prevent and treat metastasis.
Many advances in understanding the mechanisms that promote
EMT, including the identification of transcription factors and
other proteins that play key roles in these processes [3], have come
from studies of cell culture models [4,5,6,7,8]. In such systems,
a variety of extracellular signals can activate an EMT: these
include components of the extracellular matrix, soluble factors
such as members of the fibroblast growth factor (FGF) and
transforming growth factor b (TGFb) families, epidermal growth
factor, hepatocyte growth factor and others [2]. Interestingly,
some factors that under normal physiological conditions regulate
proliferation or differentiation rather than EMT, are essential for
inducing EMT-specific events in pre-malignant epithelial cells [9].
Pre-malignant cells frequently gain their ability to proliferate and
clonally expand due to constitutive activation of receptor tyrosine
kinases and downstream effectors such as RAS. Several studies
have demonstrated cooperation between growth factors and RAS
signalling in the induction of EMT [10,11,12] suggesting that
coordinated activation of multiple pathways is essential for EMT
to occur.
Bladder cancers frequently show increased signalling via FGF
receptors (FGFRs) [13,14,15]. These tumours comprise at least
two major disease entities, with distinct molecular profiles [16,17].
Activating mutations in FGFR3 are found at high frequency in
low-grade non-invasive (stage Ta) urothelial carcinoma (UC) [18]
and several studies have highlighted activated FGFR3 as
a potential therapeutic target in this subgroup [19,20,21]. As
many muscle-invasive (stage $T2) UC show upregulation of non-
mutant FGFR3 [14], this may also be a valid therapeutic target in
these poor prognosis cancers.
A high proportion of UC of all grades and stages also show
upregulated expression of FGFR1 [21]. In normal urothelial cells,
we have shown that FGFR1 signalling stimulates proliferation and
increases cell survival but does not induce invasion or changes in
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EMT (reviewed in [22]), raising the question whether FGFR1
signalling may play a different role in invasive compared to non-
invasive bladder tumours. This prompted us to investigate the
ability of FGFR1 activation to induce EMT in UC-derived cell
lines. Here we show that ligand-induced activation of ectopically
expressed FGFR1 can promote an EMT-like phenotype, with
a decrease in E-cadherin expression, morphological changes and
increased migration and invasion. Using site-directed mutagenesis
and small molecule inhibitors we have identified signalling
pathways activated by FGFR1 that contribute to EMT, including
the MAPK, PLCc and COX-2 signalling pathways. Our findings
suggest potential therapeutic approaches that may be applicable in
the prevention and/or treatment of UC metastasis.
Materials and Methods
Ethics Statement
The cell line LUCC3 was established in our laboratory from
a primary tumour sample obtained with written patient consent
and approval from the Leeds-East Research Ethics Committee.
Cell Culture and Production of Retroviruses and
Transductions
Cell lines 96-1, 94-10, 97-7 [23,24], J82 [25], VMCUB3 [26],
LUCC3 (Pitt et al. unpublished) and telomerase-immortalized
normal human urothelial cells (NHUC) [27] were used. All lines
have been authenticated in our laboratory by extensive genomic
analysis (microsatellite typing, conventional karyotypic analysis,
MFISH, array-based copy number analysis and mutation analy-
sis). Cells were grown in standard growth media at 37uCi n5 %
CO2. NHUC were maintained as described [27]. FGFR1
(NM_023110) and FGFR1 Y766F were cloned as described
[21]. FGFR1 and FGFR1 Y766F constructs were transfected into
Phoenix A packaging cells (ATCC), using siPORT
TM XP-1
transfection agent (Ambion). After 48 hours, medium was
harvested, 0.4 mm filtered and mixed in equal amounts with fresh
medium containing 8 mg/ml of polybrene (Sigma). Cells were
incubated with retroviral supernatants for 8 hours. Forty-eight
hours after transduction, cells were transferred into selection
medium containing hygromycin.
Quantitative Real-time Reverse Transcriptase-PCR for
FGFRs
Total RNA was extracted from cell lines. RNA was extracted
using Qiagen RNeasy Mini Kit (Qiagen) and 1 mg was reverse
transcribed in the presence or absence of reverse transcriptase
(Invitrogen) according to the manufacturer’s instructions. Real-
time RT-PCR analysis was performed using E-cadherin and
COX-2 Taqman probes and normalised to SDHA as an internal
control (Applied Biosystems).
Western Blotting, Cell Staining and PGE2 Analysis
Cells were lysed in Triton buffer [1% Triton-X 100, 1 mM
EDTA, and protease inhibitor cocktail (Sigma) in PBS] and lysates
cleared by centrifugation at 10000 rpm at 4uC. The protein
concentrations were determined using the BCA (bicinchonic acid)
assay (Pierce). Antibodies used for western blotting were anti-
phospho-ERK (sc-7383, Santa Cruz), ERK (sc-154, Santa Cruz),
phospho-PLCc (2821, Cell Signaling), PLCc Cell Signaling),
phospho-STAT3 (9135, Cell Signaling), STAT3, phospho-p38
(9221, Cell Signaling), p38 (9217, Cell Signaling), phospho-ATF
(9221, Cell Signaling), phospho-MEK1/2 (9121, Cell Signaling),
FGFR1 (SC-121, Santa Cruz), E-cadherin (ab1416, Abcam),
plakoglobin (p8087, Sigma) and tubulin (MCA77G, Serotec). The
Human Phospho-Kinase Antibody Array (R&D Systems) was
performed as described by the manufacturer. Briefly, the array was
blocked then incubated with 200 mg of protein extracted from
treated cells, prior to incubation with Detection Antibody
Cocktail. The Arrays were imaged and quantified using Quantity
One Software (BioRad).
For cell staining, cells were fixed on glass slides with 4%
paraformaldehyde (PFA) for 15 min, washed in PBS and
permeabilized with 0.25% triton/PBS for 5 min. Cells were
washed in PBS and incubated with Phalloidin-488 (Molecular
Probes) and DAPI.
For prostaglandin E2 (PGE2) analysis, cells were cultured with
FGF2 or arachidonic acid (Sigma) for 4 hours. Cells lysates were
made by repeated freeze thawing cycles. PGE2 was analysed in
media and lysates using the Prostaglandin E2 EIA Kit (Cayman
Chemical).
Phenotypic Assays
For transwell assays 5610
5 cells were plated per transwell in a 24
well dish in duplicate per experiment. Each experiment was
repeated three times. 5 hr after plating, media was replaced with
serum-free media with the appropriate culture conditions and left
for 24–36 hr (heparin, 10 mg/ml; FGF2, 10 ng/ml; U0126,
10 mM; BAPTA-AM, 10 mM; BIRB, 1 mM; NS-398, 20 mM;
AH-23848, 20 mM). Cultures were pre-treated for one hour (on
both sides of the chamber) prior to the addition of FGF2 to
the lower chamber. The cells that remained on the upper side of
the transwell were scraped off and the cells that migrated across
the transwell were fixed in methanol/acetone for 5 min. Cells
were stained with DAPI and the transwell imaged using Volocity
software. DAPI stain was quantified using the Volocity software.
For the Matrigel
TM assays, a layer of Matrigel
TM (Invitrogen),
mixed with an equal amount of media containing heparin or
heparin and FGF2, was placed in the transwell. 1610
5 cells were
plated on the Matrigel
TM, media was replaced after 6 hr and the
cells were incubated for 96 h. The cells were fixed in 4% PFA for
30 min, permeabilized with 0.25% triton/PBS and incubated with
Phalloidin-Alexa 488. Multiple points on each well were imaged
using a confocal microscope. For scratch assays cells were plated at
high density and cultured until confluence. Cells were scratched
with a pipette tip in two directions to enable imaging, washed
twice in serum free media, and the appropriate supplements
added. Cells were imaged after 48 hours. Cell size was measured
using the Guava EasyCyte
TM System (Guava Technologies),
according to the manufacturer’s instructions.
Results
FGFR1 Activation Induces EMT in UC Cell Lines
UC cell lines express several FGFR family members (our
unpublished data). Thus, stimulation with FGFs may activate
more than one receptor. To overcome this, we initially used a UC
cell line, 94-10, which expresses relatively low levels of FGFRs 2, 3
and 4 and almost undetectable levels of FGFR1. FGFR1 was
ectopically expressed in a polyclonal population of 94-10 cells by
retroviral transduction and expression confirmed by western
blotting (Figure S1D)). Cells expressing FGFR1 (94-10-FR1) were
stimulated with heparin or heparin and FGF2 for 72 h. 94-10-FR1
cells cultured with FGF2 developed an elongated and larger
morphology and appeared scattered compared to control cells,
suggesting that they had undergone an EMT (Figure 1A). 94-10
wild type cells showed no response to FGF2.
FGFR1 and EMT in Bladder Cancer
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during the EMT process. These include re-organisation of the
actin cytoskeleton, increased migration and invasion and de-
creased expression of E-cadherin. No changes in morphology,
actin cytoskeleton or invasion were observed in 94-10 cells
transduced with a control vector. However, 94-10-FR1 cells
cultured with FGF2 showed an altered actin cytoskeleton after
72 h (Figure 1B). Re-organisation of the actin cytoskeleton
occurred rapidly after FGFR1 stimulation, with increased
formation of stress-fibres by 30 minutes (Figure S1A). Flow
cytometry confirmed an increase in cell size (Figure S1B).
Migration was assessed using transwell (Figure 1C) and scratch-
wound assays (Figure S1C). The transwell assay demonstrated that
94-10-FR1 cells migrate towards FGF2. Invasion was measured by
plating the cells on a bed of 50% matrigel containing heparin or
heparin and FGF2 (Figure 1D). Cells were stained for actin and
imaged using confocal microscopy. Under normal conditions 94-
10 cells form spheroids. In the presence of FGF2, cells from 90%
of spheroids expressing FGFR1 invaded in streams into the
matrigel by 96 h. 94-10-FR1 cells cultured with heparin and
FGF2 also showed decreased expression of E-cadherin mRNA and
protein (Figure 1E and F).
To determine the generality of FGFR1-induced EMT in UC,
FGFR1 was expressed in five additional UC cell lines (J82,
LUCC3, 96-1, 97-7 and VMCUB3). Ectopic expression of
FGFR1 followed by FGF2 treatment induced an EMT in 3 of
the 5 lines (J82, LUCC3, and 96-1) (Figure 2). These cell lines
express higher endogenous levels of FGFR1 than 94-10 (96-
1.J82.LUCC3) and treatment with FGF2 even in the absence of
ectopic expression of FGFR1 resulted in an EMT-like phenotype
(data not shown). Activation of FGFR1 caused altered morphology
and cell scattering (Figure 2A), and a significant (Student’s T-test,
p,0.05) decrease in E-cadherin mRNA levels in all three cell lines
(Figure 2B). The effect of FGFR1 on cell migration was measured
using transwell assays. FGFR1 activation significantly (p,0.05)
increased the level of migration of J82 and LUCC3 but not 96-1
which were found to have a high basal rate of migration
independent of FGF stimulation (Figure 2C).
FGFR1 Activates Multiple Signalling Pathways in
Urothelial Carcinoma Cells
We used Human Phospho-Kinase Antibody Arrays to identify
the signalling pathways activated by FGFR1 in 94-10-FR1
(Figure 3A). Cells were cultured with FGF2 for 30 minutes and
extracts analysed on the array. ERK and p38 MAPKs (Figure 3A
box 1) and STAT3/5/6 (Figure 3A box 2) signalling pathways
were activated. Downstream effectors of these pathways were also
activated (Figure 3A boxes 1 & 3). Western blotting confirmed
activation of these pathways (Figure 3B). We have shown
previously that the MAPK pathway is activated by FGFR1 in
telomerase-immortalised normal human urothelial cells (TERT-
NHUC), though in these cells an EMT is not induced [15].
Interestingly, little activation of STATs was observed on an array
performed on normal human urothelial cells (NHUC) (data not
shown).
Previous studies have demonstrated that increased activation of
ERK, p38 and STATs is associated with induction of EMT [28].
We used a range of small molecule inhibitors to determine which
pathways are important for FGFR1-induced urothelial EMT
(Figure 3C). The MAPK pathway was inhibited using U0126, and
this also prevented p38 and STAT3 phosphorylation. p38
phosphorylation was inhibited using BIRB, and this was associated
with reduced STAT3 phosphorylation but no change in ERK
phosphorylation. Our previous studies demonstrated that PLCc
Figure 1. FGFR1 activation promotes EMT in 94-10 cells. A. 94-
10-FR1 cells were cultured with heparin or heparin and FGF2 for 72 h.
Images were taken at 72 h (bars=100 mm). B. At 72 h 94-10-FR1 cells
cultured with heparin or heparin and FGF2 were fixed and stained with
DAPI and Phalloidin-Alexa 488 (bars=30 mm). Images represent
a merged picture of DAPI and Phalloidin-Alexa 488 staining. C.
Transwell assays were used to assess changes in migration in 94-10-
FR1 and control cells. Cells which had migrated (cells on the lower part
of the transwell) were stained at 36 hr with haematoxylin. D. Invasion
assays were performed on 94-10-FR1 cells seeded onto a layer of 50%
matrigel containing heparin or heparin and FGF2. At 96 h they were
fixed, stained with Phalloidin and imaged using confocal microscopy
(bars=0.5 mm). E. Western blots for E-cadherin and tubulin (loading
control) on 94-10-FR1 and 94-10 vector control cells cultured with
heparin or heparin and FGF2 for 72 h. F. Real time RT-PCR for E-cadherin
on 94-10-FR1 cells cultured with heparin or heparin and FGF2 for 72h.
SDHA was used an internal control.
doi:10.1371/journal.pone.0038972.g001
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NHUC [21,29]. PLCc signalling activates the MAPK pathway but
is also involved in regulating intracellular free calcium levels [30]
and PLCc-mediated mechanisms are known to strongly influence
migration via regulation of the cytoskeleton [31]. To determine if
PLCc was regulating the cytoskeletal changes via modulation of
calcium flux, we cultured cells with the calcium chelator BAPTA-
AM and found no effects on signalling. Overall these results
suggest that calcium flux modulation mediated by PLCc may not
regulate ERK, but that p38 and STAT3 are regulated
downstream of ERK under these conditions Further work is
required to exclude off-target effects of BIRB.
PLCc and ERK Co-operate to Regulate Different Aspects
of Urothelial EMT
An important change that occurs during EMT and is essential
for increased cell migration is altered regulation of the actin
cytoskeleton. 94-10-FR1 cells were pre-cultured with BAPTA-AM,
U0126 or BIRB for 1 h and then treated with FGF2 for 2 h
(Figure 4) to identify pathways responsible for regulating early
changes in the actin cytoskeleton. Our results indicated that the
MAPK and the p38/STAT3 pathway do not regulate actin
cytoskeleton reorganisation in response to FGFR1 signalling.
However treatment with BAPTA-AM completely abrogated stress
fibre formation, indicating a possible role for calcium in this
process. Further work to assess calcium fluxes caused by FGF2 is
needed to confirm the role of calcium.
We then set out to identify which of these pathways effect
changes in E-cadherin expression. 94-10-FR1 cells were cultured
with BAPTA-AM, U0126 or BIRB and FGF2 for 72 h (Figure 5A).
Chelating calcium or inhibiting p38/STAT3 activation did not
prevent FGFR1-induced repression of E-cadherin levels. Howev-
er, prevention of MEK1/2 activation completely abrogated
repression of E-cadherin expression. This suggests that ERK
activation is the main downstream effector of FGFR1 that
regulates E-cadherin transcription.
Next we examined migration. Both U0126 and BAPTA-AM
significantly (p,0.05) reduced migration through transwell
membranes (Figure 5B). This suggests that both MAPK activation
and the change in the actin cytoskeleton induced by PLCc and/or
calcium are important for FGF2-induced chemotaxis. To further
validate PLCc as an important regulator of migration and EMT,
a mutant form of FGFR1, that does not contain a binding site for
PLCc (Y766F) [21], was expressed in 94-10 cells. 94-10-FR1 and
94-10-Y766F expressed equivalent levels of FGFR1 protein
(Figure S2D), but 94-10-Y766F cells showed lower levels of
ERK and p38 phosphorylation in response to FGF2 (Figure 5C).
We observed a similar effect previously in TERT-NHUC [21]. We
confirmed that activation of Y766F did not lead to phosphoryla-
tion of PLCc (Figure 5C). 94-10-Y766F showed a significantly
(p,0.05) reduced level of migration (Figure 5D) and no
reorganisation of the actin cytoskeleton (Figure 5E), indicating
that PLCc activation is important for modulating migration via
reorganisation of the actin cytoskeleton during FGFR1-induced
EMT.
Furthermore, culture of 94-10-Y766F with FGF2 did not cause
morphological and size changes (Figure S2A and B), E-cadherin
levels were not reduced as much as in 94-10-FR1 cells (Figure
S2C) and migration into Matrigel
TM was reduced (Figure 5F).
COX-2 Mediates FGFR1-induced Migration
EMT is a complex process that potentially involves a global
change in gene expression. To identify genes regulated by FGFR1,
we used microarray analysis to compare gene expression profiles of
94-10-FR1 cultured with and without FGF2 for 24 h. A literature
search was performed to identify genes that were regulated by
FGFR1 in this analysis that are also known to be associated with
invasion in UC. Cyclooxygenase-2 (COX-2) expression was
strongly induced by FGFR1 (46 fold increase, top 2% of increased
genes). We confirmed this upregulation by real-time RT-PCR.
Levels were also increased in J82, LUCC3, and 96-1 cell lines
expressing ectopic FGFR1 (Figure 6A). Numerous previous
reports have demonstrated an association of COX-2 with UC
invasion [32,33,34,35,36]. We observed a 2.5-fold increase in
expression of ZEB1, a recognised ‘‘driver’’ of EMT but no
significant change in levels of other commonly reported markers of
EMT (N-cadherin, vimentin and fibronectin).This might reflect
the time at which the mRNA was harvested and further extended
time courses are required to further elucidate changes in gene
expression.
94-10-FR1 cells were used to examine the regulation of COX-2
by FGFR1 in more detail. FGFR1 activation led to an increase in
COX-2 mRNA of 205-fold by 2 h (Figure 6B). Transcriptional,
posttranscriptional and posttranslational mechanisms are known
to regulate COX-2 expression [37]. Further work is need to study
the precise mechanisms involved in FGFR1-induced activation of
COX-2.
Next we used NS-398, a selective inhibitor of COX-2, to
determine whether increased COX-2 expression contributed to
FGFR1-induced migration (Figure 6C). NS-398 significantly
(p,0.05) reduced the level of migration and interestingly
prevented FGFR1-induced repression of E cadherin expression
increasing the level of E cadherin above control levels (data not
shown). A similar decrease in migration was observed in cells pre-
treated with AH-23848, an inhibitor of the PGE2-EP4 receptor,
further demonstrating that prostaglandin synthesis is important in
this process. Repression of E-cadherin expression was also
prevented (data not shown). We also overexpressed COX-2 in
94-10 cells and cultured cells with PGE2 but this did not promote
migration or EMT (data not shown). After further examination of
the microarray we observed that FGFR1 activation also increased
EP4 and phospholipase A2 (PLA2) expression levels. EP4 is
a receptor for prostaglandins and PLA2 is involved in releasing
arachindonic acid, which is a precursor in the production of
prostaglandins by COX-2.
As we had shown that multiple signalling pathways co-operate
to promote EMT, we examined which of these was responsible for
COX-2 regulation. Inhibition of the MAPK pathway did not
prevent the increase in COX-2 expression (Figure 6D). However,
inhibition of PLCc activation using the Y766F mutant prevented
increased COX-2 expression (Figure 6E), demonstrating that
PLCc regulates FGFR1-induced COX-2. We then measured the
levels of intracellular and secreted PGE2 in 94-10 FR1 cells
cultured with FGF2. As a control for PGE2 synthesis we also
Figure 2. FGFR1 activation induces EMT in multiple UC cell lines. A. J82, 96-1, and LUCC3 expressing ectopic FGFR1 were cultured with
heparin or heparin and FGF2. Images were taken at 72 h (Bars=100 mm). B. Real time RT-PCR for E-cadherin on cell lines cultured with heparin or
heparin and FGF2 for 72 h. Levels were normalised to SDHA and represented relative to untreated controls. C. Transwell assays were used to assess
changes in migration. Migrated cells were stained with DAPI, imaged and total staining quantified using Volocity software. Values represent relative
intensity of DAPI stain compared to the heparin only treated cells.
doi:10.1371/journal.pone.0038972.g002
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an increase in intracellular and secreted PGE2 levels. FGFR1
stimulated a significant (p,0.05) increase in intracellular but not
secreted PGE2 levels and this was dependent on COX-2 activity,
as shown by the prevention of PGE2 synthesis by NS-398
(Figure 6F).
Discussion
Recent publications have highlighted important roles for FGF
receptors in UC. The majority of studies have focused on FGFR3
but our recent findings also implicate FGFR1 [21]. It is clear that
there are at least two major groups of bladder tumours that
develop via distinct molecular pathways: low-grade non-invasive
(stage Ta) and invasive ($ stage T2) tumours [16,17]. Increased
expression of FGFR1 is found in both of these groups [15].
Previously we showed that upregulated FGFR1 signalling
promotes proliferation and survival of normal human urothelial
cells, suggesting that FGFR1 could contribute to hyperplasia early
in the development of low-grade non-invasive UC [21]. Some
growth factors, including TGFb and HGF, are known to regulate
proliferation or differentiation under normal conditions but also
induce EMT-specific events in pre-malignant or malignant
epithelial cells [9]. This raised the question of whether FGFR1
signalling may play different roles in the two distinct UC sub-
groups.
Our findings indicate that this is the case. Expression of FGFR1
in a UC cell line that expresses relatively low levels of FGFRs
induced EMT, indicating a context-dependent effect of FGFR1 in
urothelial tumor cells. In three of five other tumor cell lines tested,
this was also the case. Even without expression of ectopic FGFR1,
these cells could undergo FGF2-induced EMT, suggesting that if
FGF was present in the tissue microenvironment in vivo, the
tumours from which these cell lines were established may have
expressed an FGFR-dependent EMT phenotype. The two cell
lines that did not undergo EMT expressed higher levels of E-
cadherin (data not shown), raising the possibility that for FGFR1
to induce EMT, other events that confer a partially de-
differentiated state may be required. Also, our unpublished data
shows there is an inverse correlation between FGFR1 and E-
cadherin expression in our cell line panel demonstrating a potential
link between FGFR1 and EMT. In this context, it is interesting to
note that PPARc, a known regulator of urothelial differentiation in
vitro [38], is implicated as a negative feedback regulator of COX-2
[39,40].
FGF signalling is known to regulate EMT during development
and in models of cancer. FGFs play an integral part in regulating
migration and patterning of mesoderm during development and
FGFR1 orchestrates the EMT of the mesoderm at the primitive
streak by regulating E-cadherin expression [41]. FGFR1 activation
promotes EMT in rodent models of breast [42] and prostate [22]
cancer. Our data further broadens the range epithelial cancers in
which FGFR1 is implicated in EMT.
Other studies on bladder carcinoma cell lines have implicated
FGFs in regulation of EMT. A rat bladder carcinoma cell line,
NBT-II, can undergo EMT following addition of several growth
factors including FGF1, FGF7, and FGF10 [43] and NBT-II
carcinoma cell lines that were rendered autocrine for FGF1
activation had a much higher level of tumorigenicity [44].
Interestingly these cells showed a dual response to FGF1, with
promotion of proliferation or induction of EMT depending on
degree of confluence and cyclic AMP (cAMP) levels [45]. At low
density and low cAMP levels FGF1 induced EMT but at
confluence and high cAMP levels FGF1 promoted proliferation.
Whether cAMP levels influence FGFR1-induced phenotypes in
human bladder cancer cell lines needs to be investigated.
Our results indicate that FGFR1 activates several signalling
pathways including activation of ERK, p38 and STATs. Previous
Figure 3. Signaling downstream of FGFR1 in 94-10 cells. A. The
Human Phospho-Kinase Array was performed to examine FGFR1
signalling. Boxes 1, 2 and 3 represent activated proteins from the
MAPK, STAT and downstream effectors of MAPK induced signaling
cascades, respectively. B. Confirmation by Western blotting of the
phosphorylated proteins identified in the Human Phospho-Kinase
Array. Vector controls and FGFR1-expressing cells were cultured with
heparin and FGF2 for indicated time periods (minutes). Lysates were
harvested and used for Western blotting. C. Western blots showing
inhibition of specific pathways using small molecule inhibitors. 94-10-
FR1 cells were cultured with BAPTA-AM, U0126 or BIRB for 1 hr prior to
addition of FGF2 for 10 min.
doi:10.1371/journal.pone.0038972.g003
FGFR1 and EMT in Bladder Cancer
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of heparin or heparin and FGF2 for 2 h. Cells were fixed, stained with Phalloidin and DAPI, and imaged (bars=30 mm). Images represent combined
DAPI and Phalloidin staining.
doi:10.1371/journal.pone.0038972.g004
FGFR1 and EMT in Bladder Cancer
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promoting EMT [46,47,48]. To identify the pathway(s) responsi-
ble for inducing EMT we used a range of inhibitors to determine
their effect on FGFR1-induced phenotypic and functional
changes. MEK1/2 inhibition by U0126 prevented FGFR1-
induced EMT, reducing both FGFR1-driven migration and
regulation of E-cadherin, strongly suggesting that FGFR1 exerts
its effects on cell morphology and oncogenic functions via
regulation of the MEK-ERK pathway. Similarly, the RAS-
MEK-ERK cascade appears to be mediate TGFb-induced EMT
in pancreatic cancer cells [49].
We found that PLCc activation also plays an integral part in
regulating FGFR1-induced urothelial EMT. Activation of PLCc
regulated remodelling of the actin cytoskeleton that effected
morphological change and promoted migration. Modulation of
PLCc effects using the calcium chelator BAPTA-AM or by
expressing a mutant form of FGFR1 that cannot activate PLCc
[50] prevented actin cytoskeleton remodelling and reduced
migration. PLCc is highly expressed in several tumour types
[51,52] and has been shown to play a critical role in cell migration
and invasion [53,54,55]. One study has shown that PLCc
activation is not required for FGF-induced motility in L6 and
CHO cell lines [56]. Thus, these non-cancer derived cell lines
respond similarly to normal human urothelial cells in which we
have shown no effect of PLCc activation on migration (data not
shown). This implies that a molecular switch occurs during cancer
development that facilitates the effect of PLCc on migration and
invasion.
We found that COX-2 was strongly upregulated following
FGFR1 activation. Immunohistochemistry analyses have demon-
strated that COX-2 expression is increased in invasive UC
[32,34,35,36] and that the highest levels of expression are found
observed at the invasive front [33], suggesting COX-2 is intimately
involved in regulating UC invasion. A recent paper also describes
a reciprocal correlation between expression of COX-2 and E-
cadherin in UC [57]. Our results add weight to these observations
and identify a mechanism by which COX-2 may be regulated in
the significant proportion of aggressive UC that express high levels
of FGFR1 [21].
Activated FGFR1 increased intracellular PGE2 but we could
not detect an increase in secreted PGE2. However, culture with
arachidonic acid, showed that these cells can metabolise this
precursor to produce secreted PGE2. This may indicate the
existence of a novel FGF-dependent COX-2 signalling pathway
that causes an increase in intracellular PGE2 levels that is involved
in regulating migration.
Our results indicate that PLCc mediates both upregulation of
COX-2 and downregulation of E-cadherin, but to a lesser extent
than the MAPK pathway. Inhibition of COX-2 using NS-398 in
this system prevented FGFR1-induced repression of E-cadherin.
Jang et al have shown a similar effect in a bladder cancer cell line,
with ectopic expression of COX-2 or culture with PGE2 leading to
reduced E-cadherin expression [57]. Cells lacking PLA2 show
Figure 5. Regulation of E-cadherin and migration. A. Real time
RT-PCR for E-cadherin. levels. 94-10-FR1 cells were cultured in the
presence of heparin or heparin and FGF2 with or without U0126,
BAPTA-AM or BIRB for 72 h. mRNA was harvested, cDNA made and used
for real-time PCR. Levels were normalised to SDHA and standardised to
heparin control. B. The effect of the inhibitors on migration was
measured by transwell assay. Cells were seeded in the upper chamber,
pretreated with inhibitors for 1 hr and fixed and stained after 24 h.
Values represent percentage intensity of DAPI stained migrated cells
compared to cells cultured with FGF2. C. Western blot showing
activation of pathways in 94-10-FR1 and 94-10-Y766F expressing cells.
Cells were cultured with either heparin or heparin and FGF2 for 10 min.
D. Transwell assay for 94-10 vector control, 94-10-FR1 and 94-10-Y766F
cells cultured with heparin and FGF2. Values represent percentage
intensity of DAPI stain in the lower chamber compared to 94-10-FR1
cells. E. 94-10-FR1 and 94-10-Y766F cells were cultured with heparin or
heparin and FGF2 for 2 h. Cells were stained with DAPI and Phalloidin
to examine changes in FGF2-induced actin cytoskeleton (bars=30 mm).
F. FGFR1 and Y766F cells were grown on matrigel in a transwell for 96 h
before imaging. FGF2 was used as a chemoattractant in the lower
chamber. Arrows indicate regions of invasion (bars=0.5 mm).
doi:10.1371/journal.pone.0038972.g005
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have a regulatory effect on PLA2 activity [58]. As PLCc is
involved in regulating calcium flux and the calcium chelator
BAPTA-AM repressed migration, this suggests FGFR1 coordi-
nates activation of multiple proteins and molecules involved in
prostaglandin synthesis which is an important pathway that
mediates migration and EMT.
In conclusion our data strongly suggests that FGFR1 regulates
different processes in the two types of UC. As previously described
FGFR1 expression in non-invasive UC promotes proliferation and
survival [21], our data now demonstrates that in invasive UC
FGFR1 mediates EMT and invasion. By deciphering the
mechanisms that promote this phenotype our study has identified
that FGFR1 activation of the MAPK pathway is critical for EMT
but PLCc activation also contributes to the migratory phenotype.
To our knowledge this is the first paper to describe that FGFR1
activation promotes prostaglandin synthesis in UC. We have also
identified numerous potential therapeutic targets (FGFR1,
MAPK, PLCc and COX-2). We envisage inhibition of FGFR1
could benefit patients suffering from both non-invasive and
invasive subtypes while COX-2 inhibition could benefit patients
diagnosed with invasive disease. A clinical trial utilising COX-2
inhibitor is in progress and it will be interesting to see the clinical
benefit of this inhibition.
Supporting Information
Figure S1 A. Actin cytoskeletal changes in 94-10-FR1 cells
cultured with FGF2 and fixed at the specific time points (minutes)
shown (bars=30 mm). B. Flow cytometry results indicating
increased cell size (FSC) in FGF2 treated 94-10-FR1 cells. C.
Scratch assay demonstrating increase migration of 94-10-FR1 cells
compared to control (bars=100 mm). D. Western blot showing
expression of FGFR1 in 94-10 vector controls and cells expressing
FGFR1.
(TIF)
Figure S2 A. 94-10-Y766F show little change in morphology
after culture with FGF2 compared to 94-10-FR1 cells
(bars=100 mm). B. Flow cytometry showing no change in cell
size of 94-10-Y766F cells culture with FGF2. C. Western blot
showing E-cadherin and plakoglobin expression levels in 94-10-
FR1 and 94-10-Y766F cells cultured with heparin or heparin and
FGF2 for 72 h. Tubulin was used as loading control. D. Western
blot showing levels of FGFR1 protein in 94-10-FR1 and 94-10-
Y766F cells. Tubulin was used as loading control.
(TIF)
Author Contributions
Conceived and designed the experiments: DCT MAK MAH. Performed
the experiments: DCT EWB PML. Analyzed the data: DCT EWB PML
MAH MAK. Wrote the paper: DCT EWB PML MAH MAK.
References
1. Thiery JP (2002) Epithelial-mesenchymal transitions in tumour progression. Nat
Rev Cancer 2: 442–454.
2. Thiery JP, Acloque H, Huang RY, Nieto MA (2009) Epithelial-mesenchymal
transitions in development and disease. Cell 139: 871–890.
3. Thiery JP, Sleeman JP (2006) Complex networks orchestrate epithelial-
mesenchymal transitions. Nat Rev Mol Cell Biol 7: 131–142.
4. Bakin AV, Tomlinson AK, Bhowmick NA, Moses HL, Arteaga CL (2000)
Phosphatidylinositol 3-kinase function is required for transforming growth factor
beta-mediated epithelial to mesenchymal transition and cell migration. J Biol
Chem 275: 36803–36810.
5. Bhowmick NA, Ghiassi M, Bakin A, Aakre M, Lundquist CA, et al. (2001)
Transforming growth factor-beta1 mediates epithelial to mesenchymal transdif-
ferentiation through a RhoA-dependent mechanism. Mol Biol Cell 12: 27–36.
Figure 6. FGFR1 induces expression of COX-2. A. Real time RT-
PCR for COX-2 on cell lines expressing ectopic FGFR1 cultured with
heparin and FGF2 for 24 h. Values were standardised to cells cultured
with heparin alone and represent fold increase compared to controls. B.
Real-time RT-PCR for COX-2 in 94-10-FR1 cells cultured with heparin and
FGF2 for the indicated time points. Results are represented as fold
change compared to untreated cells. C. Transwell assays comparing the
effects of COX-2 and EP4 inhibitors on FGFR1-induced migration. Values
represent relative percentage of migrated cells (as measured by DAPI
stain) compared to 94-10-FR1 cells cultured with heparin and FGF2. D.
Real time RT-PCR for COX-2 in 94-10-FR1 cells cultured with heparin or
heparin and FGF2 for 1 h. Cells were pre-treated for 1h with and
without U0126 and results are represented as a fold-change compared
to heparin alone. E. Real-time RT-PCR for COX-2 expression in 94-10-
Y766F cells cultured with heparin and FGF2 for 1 h. All real time RT-PCR
experiments were normalised to SDHA. F. PGE2 levels were measured
by an enzyme immunoassay in lysates (black bars) and media (gray
bars) from cells cultured with heparin; heparin and FGF2; heparin, FGF
and NS-398; or arichidonic acid (AA) for 4 h.
doi:10.1371/journal.pone.0038972.g006
FGFR1 and EMT in Bladder Cancer
PLoS ONE | www.plosone.org 9 June 2012 | Volume 7 | Issue 6 | e389726. Miettinen PJ, Ebner R, Lopez AR, Derynck R (1994) TGF-beta induced
transdifferentiation of mammary epithelial cells to mesenchymal cells: in-
volvement of type I receptors. J Cell Biol 127: 2021–2036.
7. Piek E, Moustakas A, Kurisaki A, Heldin CH, ten Dijke P (1999) TGF-(beta)
type I receptor/ALK-5 and Smad proteins mediate epithelial to mesenchymal
transdifferentiation in NMuMG breast epithelial cells. J Cell Sci 112 (Pt 24):
4557–4568.
8. Savagner P, Yamada KM, Thiery JP (1997) The zinc-finger protein slug causes
desmosome dissociation, an initial and necessary step for growth factor-induced
epithelial-mesenchymal transition. J Cell Biol 137: 1403–1419.
9. Gotzmann J, Mikula M, Eger A, Schulte-Hermann R, Foisner R, et al. (2004)
Molecular aspects of epithelial cell plasticity: implications for local tumor
invasion and metastasis. Mutat Res 566: 9–20.
10. Gotzmann J, Huber H, Thallinger C, Wolschek M, Jansen B, et al. (2002)
Hepatocytes convert to a fibroblastoid phenotype through the cooperation of
TGF-beta1 and Ha-Ras: steps towards invasiveness. J Cell Sci 115: 1189–1202.
11. Janda E, Lehmann K, Killisch I, Jechlinger M, Herzig M, et al. (2002) Ras and
TGF[beta] cooperatively regulate epithelial cell plasticity and metastasis:
dissection of Ras signaling pathways. J Cell Biol 156: 299–313.
12. Oft M, Peli J, Rudaz C, Schwarz H, Beug H, et al. (1996) TGF-beta1 and Ha-
Ras collaborate in modulating the phenotypic plasticity and invasiveness of
epithelial tumor cells. Genes Dev 10: 2462–2477.
13. Munro NP, Knowles MA (2003) Fibroblast growth factors and their receptors in
transitional cell carcinoma. J Urol 169: 675–682.
14. Tomlinson DC, Baldo O, Harnden P, Knowles MA (2007) FGFR3 protein
expression and its relationship to mutation status and prognostic variables in
bladder cancer. J Pathol 213: 91–98.
15. Tomlinson DC, Knowles MA (2010) Altered splicing of FGFR1 is associated
with high tumor grade and stage and leads to increased sensitivity to FGF1 in
bladder cancer. Am J Pathol 177: 2379–2386.
16. Knowles MA (2006) Molecular subtypes of bladder cancer: Jekyll and Hyde or
chalk and cheese? Carcinogenesis 27: 361–373.
17. Wu XR (2005) Urothelial tumorigenesis: a tale of divergent pathways. Nat Rev
Cancer 5: 713–725.
18. Cappellen D, De Oliveira C, Ricol D, de Medina S, Bourdin J, et al. (1999)
Frequent activating mutations of FGFR3 in human bladder and cervix
carcinomas. Nat Genet 23: 18–20.
19. Bernard-Pierrot I, Brams A, Dunois-Larde C, Caillault A, Diez de Medina SG,
et al. (2006) Oncogenic properties of the mutated forms of fibroblast growth
factor receptor 3b. Carcinogenesis 27: 740–747.
20. Qing J, Du X, Chen Y, Chan P, Li H, et al. (2009) Antibody-based targeting of
FGFR3 in bladder carcinoma and t(4;14)-positive multiple myeloma in mice.
J Clin Invest 119: 1216–1229.
21. Tomlinson DC, Lamont FR, Shnyder SD, Knowles MA (2009) Fibroblast
growth factor receptor 1 promotes proliferation and survival via activation of the
mitogen-activated protein kinase pathway in bladder cancer. Cancer Res 69:
4613–4620.
22. Acevedo VD, Gangula RD, Freeman KW, Li R, Zhang Y, et al. (2007)
Inducible FGFR-1 activation leads to irreversible prostate adenocarcinoma and
an epithelial-to-mesenchymal transition. Cancer Cell 12: 559–571.
23. Sarkar S, Julicher KP, Burger MS, Della Valle V, Larsen CJ, et al. (2000)
Different combinations of genetic/epigenetic alterations inactivate the p53 and
pRb pathways in invasive human bladder cancers. Cancer Res 60: 3862–3871.
24. Yeager TR, DeVries S, Jarrard DF, Kao C, Nakada SY, et al. (1998)
Overcoming cellular senescence in human cancer pathogenesis. Genes Dev 12:
163–174.
25. O’Toole C, Price ZH, Ohnuki Y, Unsgaard B (1978) Ultrastructure, karyology
and immunology of a cell line originated from a human transitional-cell
carcinoma. Br J Cancer 38: 64–76.
26. Williams RD (1980) Human urologic cancer cell lines. Investigative Urology 17:
359–363.
27. Chapman EJ, Hurst CD, Pitt E, Chambers P, Aveyard JS, et al. (2006)
Expression of hTERT immortalises normal human urothelial cells without
inactivation of the p16/Rb pathway. Oncogene 25: 5037–5045.
28. Grunert S, Jechlinger M, Beug H (2003) Diverse cellular and molecular
mechanisms contribute to epithelial plasticity and metastasis. Nat Rev Mol Cell
Biol 4: 657–665.
29. di Martino E, L’Hote CG, Kennedy W, Tomlinson DC, Knowles MA (2009)
Mutant fibroblast growth factor receptor 3 induces intracellular signaling and
cellular transformation in a cell type- and mutation-specific manner. Oncogene
28: 4306–4316.
30. Carpenter G, Ji Q (1999) Phospholipase C-gamma as a signal-transducing
element. Exp Cell Res 253: 15–24.
31. Kolsch V, Charest PG, Firtel RA (2008) The regulation of cell motility and
chemotaxis by phospholipid signaling. J Cell Sci 121: 551–559.
32. Komhoff M, Guan Y, Shappell HW, Davis L, Jack G, et al. (2000) Enhanced
expression of cyclooxygenase-2 in high grade human transitional cell bladder
carcinomas. Am J Pathol 157: 29–35.
33. Ristimaki A, Nieminen O, Saukkonen K, Hotakainen K, Nordling S, et al.
(2001) Expression of cyclooxygenase-2 in human transitional cell carcinoma of
the urinary bladder. Am J Pathol 158: 849–853.
34. Shirahama T (2000) Cyclooxygenase-2 expression is up-regulated in transitional
cell carcinoma and its preneoplastic lesions in the human urinary bladder. Clin
Cancer Res 6: 2424–2430.
35. Shirahama T, Arima J, Akiba S, Sakakura C (2001) Relation between
cyclooxygenase-2 expression and tumor invasiveness and patient survival in
transitional cell carcinoma of the urinary bladder. Cancer 92: 188–193.
36. Wild PJ, Kunz-Schughart LA, Stoehr R, Burger M, Blaszyk H, et al. (2005)
High-throughput tissue microarray analysis of COX2 expression in urinary
bladder cancer. Int J Oncol 27: 385–391.
37. Mbonye UR, Song I (2009) Posttranscriptional and posttranslational determi-
nants of cyclooxygenase expression. BMB Rep 42: 552–560.
38. Varley CL, Stahlschmidt J, Lee WC, Holder J, Diggle C, et al. (2004) Role of
PPARgamma and EGFR signalling in the urothelial terminal differentiation
programme. Journal of cell science 117: 2029–2036.
39. Inoue H, Tanabe T, Umesono K (2000) Feedback control of cyclooxygenase-2
expression through PPARgamma. The Journal of biological chemistry 275:
28028–28032.
40. Yang WL, Frucht H (2001) Activation of the PPAR pathway induces apoptosis
and COX-2 inhibition in HT-29 human colon cancer cells. Carcinogenesis 22:
1379–1383.
41. Ciruna B, Rossant J (2001) FGF signaling regulates mesoderm cell fate
specification and morphogenetic movement at the primitive streak. Dev Cell 1:
37–49.
42. Xian W, Schwertfeger KL, Vargo-Gogola T, Rosen JM (2005) Pleiotropic
effects of FGFR1 on cell proliferation, survival, and migration in a 3D mammary
epithelial cell model. J Cell Biol 171: 663–673.
43. Thiery JP, Chopin D (1999) Epithelial cell plasticity in development and tumor
progression. Cancer Metastasis Rev 18: 31–42.
44. Jouanneau J, Moens G, Thiery JP (1999) The community effect in FGF-1
mediated tumor progression of a rat bladder carcinoma does not involve a direct
paracrine signaling. Oncogene 18: 327–333.
45. Boyer B, Thiery JP (1993) Cyclic AMP distinguishes between two functions of
acidic FGF in a rat bladder carcinoma cell line. J Cell Biol 120: 767–776.
46. Bakin AV, Rinehart C, Tomlinson AK, Arteaga CL (2002) p38 mitogen-
activated protein kinase is required for TGFbeta-mediated fibroblastic
transdifferentiation and cell migration. J Cell Sci 115: 3193–3206.
47. Yang Y, Pan X, Lei W, Wang J, Shi J, et al. (2006) Regulation of transforming
growth factor-beta 1-induced apoptosis and epithelial-to-mesenchymal transition
by protein kinase A and signal transducers and activators of transcription 3.
Cancer Res 66: 8617–8624.
48. Zuo W, Chen YG (2009) Specific activation of mitogen-activated protein kinase
by transforming growth factor-beta receptors in lipid rafts is required for
epithelial cell plasticity. Mol Biol Cell 20: 1020–1029.
49. Ellenrieder V, Hendler SF, Boeck W, Seufferlein T, Menke A, et al. (2001)
Transforming growth factor beta1 treatment leads to an epithelial-mesenchymal
transdifferentiation of pancreatic cancer cells requiring extracellular signal-
regulated kinase 2 activation. Cancer Res 61: 4222–4228.
50. Mohammadi M, Dionne CA, Li W, Li N, Spivak T, et al. (1992) Point mutation
in FGF receptor eliminates phosphatidylinositol hydrolysis without affecting
mitogenesis. Nature 358: 681–684.
51. Arteaga CL, Johnson MD, Todderud G, Coffey RJ, Carpenter G, et al. (1991)
Elevated content of the tyrosine kinase substrate phospholipase C-gamma 1 in
primary human breast carcinomas. Proc Natl Acad Sci U S A 88: 10435–10439.
52. Nomoto K, Tomita N, Miyake M, Xhu DB, LoGerfo PR, et al. (1995)
Expression of phospholipases gamma 1, beta 1, and delta 1 in primary human
colon carcinomas and colon carcinoma cell lines. Mol Carcinog 12: 146–152.
53. Price JT, Tiganis T, Agarwal A, Djakiew D, Thompson EW (1999) Epidermal
growth factor promotes MDA-MB-231 breast cancer cell migration through
a phosphatidylinositol 3’-kinase and phospholipase C-dependent mechanism.
Cancer Res 59: 5475–5478.
54. Thomas SM, Coppelli FM, Wells A, Gooding WE, Song J, et al. (2003)
Epidermal growth factor receptor-stimulated activation of phospholipase
Cgamma-1 promotes invasion of head and neck squamous cell carcinoma.
Cancer Res 63: 5629–5635.
55. Turner T, Chen P, Goodly LJ, Wells A (1996) EGF receptor signaling enhances
in vivo invasiveness of DU-145 human prostate carcinoma cells. Clin Exp
Metastasis 14: 409–418.
56. Clyman RI, Peters KG, Chen YQ, Escobedo J, Williams LT, et al. (1994)
Phospholipase C gamma activation, phosphotidylinositol hydrolysis, and calcium
mobilization are not required for FGF receptor-mediated chemotaxis. Cell
Adhes Commun 1: 333–342.
57. Jang TJ, Cha WH, Lee KS (2010) Reciprocal correlation between the expression
of cyclooxygenase-2 and E-cadherin in human bladder transitional cell
carcinomas. Virchows Arch 457: 319–328.
58. Chen L, Iijima M, Tang M, Landree MA, Huang YE, et al. (2007) PLA2 and
PI3K/PTEN pathways act in parallel to mediate chemotaxis. Dev Cell 12: 603–
614.
FGFR1 and EMT in Bladder Cancer
PLoS ONE | www.plosone.org 10 June 2012 | Volume 7 | Issue 6 | e38972